Cabergoline versus bromocriptine in suppression of lactation after cesarean delivery

Giorgio Giorda, Sangrila De Vincentiis, Tiziano Motta, Silvano Casazza, Mario Fadin, Alberto D’Alberton

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

We evaluated the efficacy of cabergoline, a new ergoline derivative, in blocking puerperal lactation in a group of women delivered by cesarean section. In a single-blind controlled trial 36 women were randomly allocated to treatment with cabergoline 1 mg in a single dose p.o. (n = 18) or bromocriptine 5 mg/day p.o. for 14 days (n = 18). Treatment was started about 50 h after delivery. Clinical assessment of breast signs and determination of serum prolactin were performed just before treatment and at 3, 5,7 and 14 days. In the cabergoline-treated group milk secretion was inhibited in 17 women (94.4%). Maximum decrease of serum prolactin was -89.7% at 5 days, and the prolactin- lowering effect of cabergoline was still present at 14 days. In the bromocriptine group milk secretion was inhibited in 16 women (88.9%). Maximum prolactin decrease (-86.9%) was reached at 3 days. Persistent side effects were comparable in the two groups. This study demonstrates that a single oral dose of 1 mg cabergoline is as effective in suppressing puerperal lactation as a full treatment with bromocriptine, even in women delivered by cesarean section.

Original languageEnglish
Pages (from-to)93-96
Number of pages4
JournalGynecologic and Obstetric Investigation
Volume31
Issue number2
DOIs
Publication statusPublished - 1991

Fingerprint

Bromocriptine
Lactation
Prolactin
Cesarean Section
Milk
Ergolines
Therapeutics
Serum
Breast
cabergoline

Keywords

  • Bromocriptine
  • Cabergoline
  • Inhibition
  • Lactation

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

Cabergoline versus bromocriptine in suppression of lactation after cesarean delivery. / Giorda, Giorgio; De Vincentiis, Sangrila; Motta, Tiziano; Casazza, Silvano; Fadin, Mario; D’Alberton, Alberto.

In: Gynecologic and Obstetric Investigation, Vol. 31, No. 2, 1991, p. 93-96.

Research output: Contribution to journalArticle

Giorda, Giorgio ; De Vincentiis, Sangrila ; Motta, Tiziano ; Casazza, Silvano ; Fadin, Mario ; D’Alberton, Alberto. / Cabergoline versus bromocriptine in suppression of lactation after cesarean delivery. In: Gynecologic and Obstetric Investigation. 1991 ; Vol. 31, No. 2. pp. 93-96.
@article{4e794562c83e42e490651324270bf796,
title = "Cabergoline versus bromocriptine in suppression of lactation after cesarean delivery",
abstract = "We evaluated the efficacy of cabergoline, a new ergoline derivative, in blocking puerperal lactation in a group of women delivered by cesarean section. In a single-blind controlled trial 36 women were randomly allocated to treatment with cabergoline 1 mg in a single dose p.o. (n = 18) or bromocriptine 5 mg/day p.o. for 14 days (n = 18). Treatment was started about 50 h after delivery. Clinical assessment of breast signs and determination of serum prolactin were performed just before treatment and at 3, 5,7 and 14 days. In the cabergoline-treated group milk secretion was inhibited in 17 women (94.4{\%}). Maximum decrease of serum prolactin was -89.7{\%} at 5 days, and the prolactin- lowering effect of cabergoline was still present at 14 days. In the bromocriptine group milk secretion was inhibited in 16 women (88.9{\%}). Maximum prolactin decrease (-86.9{\%}) was reached at 3 days. Persistent side effects were comparable in the two groups. This study demonstrates that a single oral dose of 1 mg cabergoline is as effective in suppressing puerperal lactation as a full treatment with bromocriptine, even in women delivered by cesarean section.",
keywords = "Bromocriptine, Cabergoline, Inhibition, Lactation",
author = "Giorgio Giorda and {De Vincentiis}, Sangrila and Tiziano Motta and Silvano Casazza and Mario Fadin and Alberto D’Alberton",
year = "1991",
doi = "10.1159/000293109",
language = "English",
volume = "31",
pages = "93--96",
journal = "Gynecologic and Obstetric Investigation",
issn = "0378-7346",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Cabergoline versus bromocriptine in suppression of lactation after cesarean delivery

AU - Giorda, Giorgio

AU - De Vincentiis, Sangrila

AU - Motta, Tiziano

AU - Casazza, Silvano

AU - Fadin, Mario

AU - D’Alberton, Alberto

PY - 1991

Y1 - 1991

N2 - We evaluated the efficacy of cabergoline, a new ergoline derivative, in blocking puerperal lactation in a group of women delivered by cesarean section. In a single-blind controlled trial 36 women were randomly allocated to treatment with cabergoline 1 mg in a single dose p.o. (n = 18) or bromocriptine 5 mg/day p.o. for 14 days (n = 18). Treatment was started about 50 h after delivery. Clinical assessment of breast signs and determination of serum prolactin were performed just before treatment and at 3, 5,7 and 14 days. In the cabergoline-treated group milk secretion was inhibited in 17 women (94.4%). Maximum decrease of serum prolactin was -89.7% at 5 days, and the prolactin- lowering effect of cabergoline was still present at 14 days. In the bromocriptine group milk secretion was inhibited in 16 women (88.9%). Maximum prolactin decrease (-86.9%) was reached at 3 days. Persistent side effects were comparable in the two groups. This study demonstrates that a single oral dose of 1 mg cabergoline is as effective in suppressing puerperal lactation as a full treatment with bromocriptine, even in women delivered by cesarean section.

AB - We evaluated the efficacy of cabergoline, a new ergoline derivative, in blocking puerperal lactation in a group of women delivered by cesarean section. In a single-blind controlled trial 36 women were randomly allocated to treatment with cabergoline 1 mg in a single dose p.o. (n = 18) or bromocriptine 5 mg/day p.o. for 14 days (n = 18). Treatment was started about 50 h after delivery. Clinical assessment of breast signs and determination of serum prolactin were performed just before treatment and at 3, 5,7 and 14 days. In the cabergoline-treated group milk secretion was inhibited in 17 women (94.4%). Maximum decrease of serum prolactin was -89.7% at 5 days, and the prolactin- lowering effect of cabergoline was still present at 14 days. In the bromocriptine group milk secretion was inhibited in 16 women (88.9%). Maximum prolactin decrease (-86.9%) was reached at 3 days. Persistent side effects were comparable in the two groups. This study demonstrates that a single oral dose of 1 mg cabergoline is as effective in suppressing puerperal lactation as a full treatment with bromocriptine, even in women delivered by cesarean section.

KW - Bromocriptine

KW - Cabergoline

KW - Inhibition

KW - Lactation

UR - http://www.scopus.com/inward/record.url?scp=0025869522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025869522&partnerID=8YFLogxK

U2 - 10.1159/000293109

DO - 10.1159/000293109

M3 - Article

C2 - 2037265

AN - SCOPUS:0025869522

VL - 31

SP - 93

EP - 96

JO - Gynecologic and Obstetric Investigation

JF - Gynecologic and Obstetric Investigation

SN - 0378-7346

IS - 2

ER -